ADDING COST EFFECTIVE MASS DETECTION FOR IMPROVED PRODUCTIVITY IN OLIGONUCLEOTIDE SCREENING ASSAYS

Importance of the Topic

The development of therapeutic oligonucleotides such as antisense DNA and RNAi has driven demand for robust, high-throughput analytical workflows. Ion-pair reversed-phase liquid chromatography (IP-RPLC) provides excellent selectivity, while mass spectrometry offers definitive molecular information. Integrating optical and MS detection in a single assay workflow enhances productivity and data confidence, supporting rapid screening and quality control in pharmaceutical research.

Objectives and Study Overview

This study evaluates a cost-effective analytical approach combining UV absorbance and low-cost single-quadrupole mass detection using the ACQUITY QDa mass analyzer. Key goals include:

• Assess inline orthogonal detection for synthetic oligonucleotide standards.
• Demonstrate mass accuracy and reproducibility across multiple charge states.
• Validate compatibility with data processing tools (MassLynx/MaxEnt and ProMass HR) for high-throughput screening.

Methodology and Instrumentation Used

• Chromatography
  • System: ACQUITY UPLC H-Class
  • Column: OST BEH C18, 1.7 µm, 2.1×50 mm at 60 °C
  • Mobile phases: A – H₂O with 15 mM triethylamine and 400 mM HFIP (pH 8.0); B – methanol with same additives
  • Flow: 0.2 mL/min with a stepped gradient optimized for polyT standards and ssRNA strands
• Detection
  • UV: ACQUITY UPLC TUV at 260 nm
  • Mass: ACQUITY QDa, negative electrospray mode, 410–1250 Da scan range, cone voltage 20 V, capillary 0.8 kV, probe temperature 600 °C
• Data Processing
  • MassLynx with MaxEnt1 algorithm for deconvolution
  • ProMass HR for batch deconvolution and high-throughput identity screening

Main Results and Discussion

The QDa analyzer reliably detected up to nine charge states for oligonucleotide standards from 15 nt to 35 nt. Charge-state reproducibility fell within ±0.2 Da instrument specification with RSDs below 0.1 %. Deconvoluted zero-charge masses matched expected molecular weights within +0.0 to +0.7 Da using MassLynx. ProMass HR compatibility testing over a 1 min spectral window demonstrated mass accuracy from –0.1 to +0.5 Da, suitable for nominal-mass screening. Inline orthogonal detection improved analytical confidence and supported rapid interpretation of complex spectra.

Benefits and Practical Applications

• Enhanced productivity via one-pass simultaneous UV and MS detection
• Reliable mass confirmation reduces false positives in screening
• Straightforward deconvolution accelerates decision making
• Seamless integration with automated, high-throughput data processing platforms

Future Trends and Applications

Advances in single-quadrupole MS sensitivity and software deconvolution will further streamline oligonucleotide analysis. Emerging areas include real-time monitoring in automated synthesis, integration with machine-learning algorithms for spectral interpretation, and expansion into modified and high-molecular-weight oligonucleotide therapeutics. Lower cost mass detectors will become standard components in quality control laboratories.

Conclusion

Combining ACQUITY UPLC UV detection with the compact ACQUITY QDa mass analyzer offers a cost-effective, reliable workflow for oligonucleotide screening assays. The approach delivers consistent mass accuracy, supports high-throughput operations, and strengthens data integrity in therapeutic oligonucleotide development.